Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?

OBJECTIVES To describe and evaluate the different price control strategies implemented in Norway after its accession to the European Economic Area (1994-2004). METHODS Interviews with ten key persons who had broad insight into the field in question were held. All the available literature was reviewed. RESULTS Direct price control involving international reference pricing of prescription drugs, and the subsequent price revisions, that occurred from the year 2000 onwards, resulted in predictable and substantial price reductions. With respect to the indirect methods which targeted the off-patent market, the price reductions resulting from reference-based pricing (1993-2000) were only marginal and the achieved savings derived mainly from increased patients' charges. The introduction of generic substitution in 2001 led to increased market shares for non-branded products, but discounts from the manufacturers were not reflected in retail prices. An index price system (2003-2004) was therefore created; but as it entailed negative economical incentives for the pharmacy chains, the price changes did not meet the expectations. CONCLUSION The direct pricing strategy, i.e. the international reference pricing, was considered to be the most successful method. In contrast, due to the unpredictability of the market situation, the resulting effects of the indirect methods, i.e. reference-based pricing, generic substitution, and index pricing, were more limited.

[1]  A D Oxman,et al.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2006, The Cochrane database of systematic reviews.

[2]  Xuan Yu,et al.  Pharmaceutical supply chain in China: current issues and implications for health system reform. , 2010, Health policy.

[3]  Anders Anell,et al.  Deregulating the pharmacy market: the case of Iceland and Norway. , 2005, Health policy.

[4]  S. Morgan,et al.  Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. , 2004, Health policy.

[5]  Y. R. Wang,et al.  The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s , 2003, Health economics.

[6]  S. Schneeweiss Reference drug programs: effectiveness and policy implications. , 2007, Health policy.

[7]  M. Mrazek Comparative approaches to pharmaceutical price regulation in the European Union. , 2002, Croatian medical journal.

[8]  J. Mauskopf Value in health: "bridging the gap" among our disciplines. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  J. M. Traulsen,et al.  Cost-Containment as Part of Pharmaceutical Policy , 2005, Pharmacy World and Science.

[10]  S. Strøm,et al.  Price regulation and generic competition in the pharmaceutical market , 2006, The European Journal of Health Economics.

[11]  P. Souverein,et al.  Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. , 2007, British journal of clinical pharmacology.

[12]  L. Garrison,et al.  The drug budget silo mentality in Europe: an overview. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  L. Garattini,et al.  Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. , 2007, Health policy.

[14]  J. Avorn,et al.  Pharmaceutical cost containment with reference-based pricing: time for refinements. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  J. McNeil,et al.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. , 2002, PharmacoEconomics.

[16]  J. Sverre,et al.  Pricing and reimbursement of pharmaceuticals in Norway , 2002, The European Journal of Health Economics.

[17]  M. Dickson,et al.  Pharmaceutical reference prices. How do they work in practice? , 1998, PharmacoEconomics.

[18]  P. Grootendorst,et al.  A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. , 2006, Health economics.

[19]  S. Simoens International comparison of generic medicine prices , 2007, Current medical research and opinion.

[20]  P. Norris The impact of European harmonisation on Norwegian drug policy. , 1998, Health policy.

[21]  Pricing and Reimbursement of Pharmaceuticals. A New Culture for the Community Pharmacist. , 1998, Pharmacy World and Science.

[22]  F. Andersson Norway's pivotal role in regulatory health economics and pharmaceutical cost containment--what can other countries learn? , 1992, Health policy.

[23]  J. Puig-Junoy,et al.  Review of the literature on reference pricing. , 2000, Health policy.

[24]  J. Lexchin A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. , 2006, Health Policy.

[25]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.